Atlas Trials

Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers

Clinical trial NCT03799731 · COMPLETED

Trial details

NCT number
NCT03799731
Sponsor
GamaMabs Pharma
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Colorectal Cancer
Start date
2018-07-11
Primary completion
2021-01-19
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.